CEL-SCI announces neoadjuvant nivolumab plus chemotherapy study published
CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...
Business Wire2d
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patient…
Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...
Zacks.com on MSN6d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or ...
GlobalData on MSN6d
EC approves BMS’ Opdivo and Yervoy combo for HCC
The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the ...
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkersCM24 ...
Exelixis: Pinning Hopes On Cracking One Of The Toughest Nuts
Exelixis' future depends on trial outcomes and patent risks. Find out why EXEL stock is a "Sell" despite cabozantinib's ...
The Manila Times6d
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
The full audited consolidated financial statements as of and for the year ended December 31, 2024, can be found in BioNTech's Annual Report on Form 20-F filed today with the United States Securities ...
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.